Quest Diagnostics (Ibrutinib Royalty Rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Undetermined
  • Financing Rounds
  • 2

Quest Diagnostics (Ibrutinib Royalty Rights) General Information

Description

Provider of diagnostic information services and holder of drug-royalty rights.The company owns the royalty rights on commercialization of ibrutinib, an experimental cancer therapy that inhibits the Bruton's tyrosine kinase (BTK) enzyme.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Healthcare Services
Acquirer
Primary Office
  • Secaucus, NJ
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Quest Diagnostics (Ibrutinib Royalty Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Quest Diagnostics (Ibrutinib Royalty Rights)‘s full profile, request access.

Request a free trial

Quest Diagnostics (Ibrutinib Royalty Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Quest Diagnostics (Ibrutinib Royalty Rights)‘s full profile, request access.

Request a free trial